System for detecting infection in synovial fluid
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G01N-033/558
G01N-033/68
출원번호
US-0371965
(2012-10-22)
등록번호
US-10139405
(2018-11-27)
국제출원번호
PCT/US2012/061350
(2012-10-22)
국제공개번호
WO2013/112216
(2013-08-01)
발명자
/ 주소
Deirmengian, Carl
Birkmeyer, Richard C.
Kardos, Keith
Kilmartin, Patrick
Cameron, Alexander
Schiller, Kevin
Chung, Eun Kyung
출원인 / 주소
CD Diagnostics, Inc.
대리인 / 주소
Schwegman Lundberg & Woessner, P.A.
인용정보
피인용 횟수 :
0인용 특허 :
18
초록▼
The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not
The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.
대표청구항▼
1. A method of treating joint pain in a subject, the method comprising; applying a fluid sample obtained from the joint to a system comprising a device, cartridge or strip having a flow path through which a fluid sample can move, the flow path comprising:a) a first region comprising a first detectio
1. A method of treating joint pain in a subject, the method comprising; applying a fluid sample obtained from the joint to a system comprising a device, cartridge or strip having a flow path through which a fluid sample can move, the flow path comprising:a) a first region comprising a first detection reagent that specifically binds a human neutrophil α-defensin; andb) a second region comprising an internal control detector reagent; andtreating the subject with an anti-bacterial agent if greater than 5,000 ng/ml of human neutrophil α-defensin is detected in the fluid sample, or treating the subject for aseptic-inflammation if less than 5,000 ng/ml of human neutrophil α-defensin is detected in the fluid sample. 2. The method of claim 1, wherein the joint is a replacement joint or a prosthetic joint. 3. The method of claim 1, wherein the internal control detector reagent specifically binds hyaluronic acid, mucopolysaccharide, glucosamine, chondroitin sulfate, cartilage oligomeric matrix protein, lumican, lubricin, or a combination thereof. 4. The method of claim 1, wherein the α-defensin in the fluid sample is detected at a concentration that is at least about twice the concentration of the α-defensin in a synovial fluid sample from a normal joint. 5. The method of claim 1, wherein the first detection reagent detects the α-defensin at a concentration that is at least about 7,000 ng/ml. 6. The method of claim 1, wherein the flow path further comprises a second detection reagent that specifically binds a second biomarker of joint infection. 7. The method of claim 1, further comprising: mixing the fluid sample obtained from the joint with an assay buffer; andapplying the fluid sample and assay buffer mixture to the system. 8. The method of claim 7, wherein the assay buffer dilutes the fluid sample to enhance the ability to pipette and transfer the fluid sample. 9. The method of claim 7, wherein the assay buffer comprises a reagent that lyses cellular components present in the fluid sample. 10. The method of claim 9, wherein the reagent is a non-ionic surfactant. 11. The method of claim 7, wherein the assay buffer comprises a reagent that preserves the fluid sample and stabilizes biomarkers present in the fluid sample. 12. The method of claim 7, wherein the assay buffer comprises a reagent that inhibits an interfering component present in the fluid sample. 13. The method of claim 7, wherein the assay buffer maintains a pH in the range of about 6-8. 14. The method of claim 7, wherein with the assay buffer dilutes the fluid sample by a factor of between about 5,000 and about 10,000.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (18)
Chee Mark ; Cronin Maureen T. ; Fodor Stephen P. A. ; Huang Xiaohua X. ; Hubbell Earl A. ; Lipshutz Robert J. ; Lobban Peter E. ; Morris MacDonald S. ; Sheldon Edward L., Arrays of nucleic acid probes on biological chips.
de Jaeger Nikolaas C. J. (Hove BEX) Monbaliu Marcel J. (Mortsel BEX) Noppe Marcus J. M. (Kalmthout BEX) Konings Frank J. (Antwerpen BEX), Immunoassay using colorable latex particles.
Pirrung Michael C. (Durham NC) Read J. Leighton (Palo Alto CA) Fodor Stephen P. A. (Palo Alto CA) Stryer Lubert (Stanford CA), Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof.
Miyauti Satoshi,JPX ; Horie Katuyuki,JPX, Method and measurement kit for assay of normal agrecan, and method for evaluation of informations on the joint.
Subrahmanyam V. Yerramilli ; Yatindra Prashar ; Peter Newburger ; Jon Goguen ; Sherman M. Weissman, Process to study changes in gene expression in granulocytic cells.
Maslyn Timothy J. ; Au-Young Janice ; Hillman Jennifer L. ; Hibbert Harold ; Akerblom Ingrid E. ; Cheng Rachel J. ; Tang Yuanhua T., Project-based full-length biomolecular sequence database.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.